4 active not recruiting, 2 completed, 2 no longer available, 2 recruiting. 6 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Ocugen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD OCU410 - Dry Age-related Macular Degeneration | Phase 3 | Recruiting | Ocugen | 237 | 2026-08-11 | 2026-08-19 |
| A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa Sub-Retinal Administration of OCU400-301 - Retinitis Pigmentosa | Phase 3 | Active not recruiting | Ocugen | 140 | 2024-06-18 | 2026-07-31 |
| Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) OCU200 - Center Involved Diabetic Macular Edema, Diabetic Macular Edema | Phase 1 | Recruiting | Ocugen | 24 | 2024-01-13 | 2026-07-31 |
| A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease OCU410ST - Stargardt Disease | Phase 2 / Phase 3 | Active not recruiting | Ocugen | 51 | 2023-08-25 | 2026-07-31 |
| Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy OCU410 - Geographic Atrophy | Phase 1 / Phase 2 | Active not recruiting | Ocugen | 60 | 2023-02-23 | 2026-10-30 |
| Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults BBV152 - COVID-19 | Phase 2 / Phase 3 | Unknown | Ocugen | 400 | 2022-02-20 | 2023-03-27 |
| Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose - Retinitis Pigmentosa, Leber Congenital Amaurosis | Phase 1 / Phase 2 | Active not recruiting | Ocugen | 22 | 2022-01-24 | 2026-07-31 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease Brimonidine Tartrate, Placebos - Graft Versus Host Disease, Ocular Surface Disease | Phase 3 | Terminated | Ocugen | 59 | 2018-12-23 | 2022-07-06 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) Brimonidine Tartrate, Placebos - Dry Eye | Phase 3 | Completed | Ocugen | 252 | 2018-12-03 | 2022-07-18 |
| Dry Eye Disease Study With Brimonidine Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose - Dry Eye | Phase 2 | Completed | Ocugen | 84 | 2017-09-06 | 2022-07-06 |
| Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) Brimonidine 0.15%, Brimonidine 0.075%, Placebo - Dry Eye, Ocular Graft vs Host Disease | Phase 1 / Phase 2 | Terminated | Sandeep Jain, MD | 15 | 2016-05-01 | 2019-11-08 |
| Expanded Access Program for RP in Adults OCU400 - Retinitis Pigmentosa | No longer available | Ocugen | 2026-10-02 | |||
| Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older BBV152 - COVID-19 | No longer available | Ocugen | 2022-09-22 |
Dry Eye Syndromes (3) · Retinitis Pigmentosa (3) · COVID-19 (2) · Enhanced S-Cone Syndrome (1) · Geographic Atrophy (1) · Graft vs Host Disease (1) · Leber Congenital Amaurosis (1) · Meckel Syndrome, Type 4 (1) · Meibomian Gland Dysfunction (1) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1) · Stargardt Disease (1)
Brimonidine Tartrate (4) · BBV152 COVID-19 vaccine (2) · Carboxymethylcellulose Sodium (1) · Lubricant Eye Drops (1)
United States (13) · Canada (1)
Mohamed Genead, MD (7) · Jennifer Henrick, RN, MS (6) · Huma Qamar, MD, MPH, CMI (1) · Jennifer Henrick (1) · Sandeep Jain, MD (1)